ABIMMUNE BIOPHARMA Trademark

Trademark Overview

On Monday, September 17, 2018, a trademark application was filed for ABIMMUNE BIOPHARMA with the United States Patent and Trademark Office. The USPTO has given the ABIMMUNE BIOPHARMA trademark a serial number of 88120156. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 8, 2020. The ABIMMUNE BIOPHARMA trademark is filed in the Treatment & Processing of Materials Services category with the following description:

Custom manufacture of proteins and antibodies by pharmaceutical compounders
abimmune biopharma

General Information

Serial Number88120156
Word MarkABIMMUNE BIOPHARMA
Filing DateMonday, September 17, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 8, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 27, 2019

Trademark Statements

Disclaimer with Predetermined Text"BIOPHARMA"
Goods and ServicesCustom manufacture of proteins and antibodies by pharmaceutical compounders

Classification Information

International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateSunday, September 23, 2018
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNOT AVAILABLE
Party Type20 - Owner at Publication
Legal Entity Type01 - Individual
AddressRANCHO SANTA FE, CA 92067
Party NameNOT AVAILABLE
Party Type10 - Original Applicant
Legal Entity Type01 - Individual
AddressRANCHO SANTA FE, CA 92067

Trademark Events

Event DateEvent Description
Monday, June 8, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, June 8, 2020ABANDONMENT - NO USE STATEMENT FILED
Tuesday, October 22, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 27, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 27, 2019PUBLISHED FOR OPPOSITION
Wednesday, August 7, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, July 19, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, July 19, 2019EXAMINER'S AMENDMENT ENTERED
Friday, July 19, 2019NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, July 19, 2019EXAMINERS AMENDMENT E-MAILED
Friday, July 19, 2019EXAMINERS AMENDMENT -WRITTEN
Friday, July 12, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, July 12, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, July 5, 2019ASSIGNED TO LIE
Monday, July 1, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, July 1, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, January 2, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, January 2, 2019NON-FINAL ACTION E-MAILED
Wednesday, January 2, 2019NON-FINAL ACTION WRITTEN
Thursday, December 27, 2018ASSIGNED TO EXAMINER
Sunday, September 23, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, September 20, 2018NEW APPLICATION ENTERED IN TRAM

Related Keywords

biopharma abimmune pharmaceutical compounders antibodies proteins manufacture custom